Help us improve Portfolio Grader.

Help us improve Portfolio Grader.

Blue Chip Growth

Stock Report: "SciClone Pharmaceuticals, Inc." (SCLN) Report Updated: Sep 16, 2017 | Print This Page

Get more stock ratings by Louis Navellier

"SciClone Pharmaceuticals, Inc." (SCLN)

Rating: Hold Volatility: Conservative
Total Grade: C Industry: Pharmaceuticals

Stock Analysis

Rating: Monthly View

September October November December January February March April May June July August

Rating: Weekly View

This Week: C down no change
Last Week: C same no change
Two Weeks Ago: C up no change
service keys

"SciClone Pharmaceuticals, Inc."© quotemedia

Company Profile

SciClone Pharmaceuticals, Inc., a specialty pharmaceutical company, provides therapies for oncology, infectious diseases, and cardiovascular disorders in the People’s Republic of China, the United States, and Hong Kong. Its lead product is ZADAXIN, which is used for the treatment of hepatitis B and hepatitis C viruses, and certain cancers, as well as for use as a vaccine adjuvant, and as a chemotherapy adjuvant for cancer patients with weakened immune systems. The company also focuses on development ZADAXIN for the treatment of sepsis. ZADAXIN has approval in approximately 30 countries, which include China, the Pacific Rim, Latin America, Eastern Europe, and the Middle East regions. The company markets and sells ZADAXIN through distribution arrangements, local importers, and distributors. In addition, it markets approximately seven partnered products in China, including Aggrastat, an interventional cardiology product. Further, the company holds license, promotion, distribution, or marketing agreements with various parties for products, including DC Bead, Holoxan, Mesna, Endoxan, Methotrexate, Estracyt, Farlutal, Neucardin, ProFlow, Angiomax, and Cleviprex. SciClone Pharmaceuticals, Inc. also has an agreement with MEDA Pharma GmbH & Co. KG for the development of Tramadol. The company was founded in 1989 and is headquartered in Foster City, California.